Please assess the completion status of the following clinical trial:

Trial Title: OBE001 Phase 2 Dose-finding Study Versus Placebo in Women Undergoing Embryo Transfer in the Context of IVF-ICSI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria~1. Women with medically indicated IVF or ICSI using her own oocytes.~2. GnRH antagonist protocol, a single injection of hCG for triggering final follicular maturation and luteal phase support with vaginal micronized progesterone.~3. Evidence of uterine contractions by transvaginal ultrasound at baseline.~Key Exclusion Criteria~1. Blastocyst stage or frozen-thaw transfers~2. Clinically significant abnormalities in ECG, vital signs, physical examination or clinical laboratory results~3. Severe endometriosis and/or adenomyosis or risk of ovarian hyper stimulation syndrome

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 36 Years
- Healthy Volunteers: f

Study Arms:
- OBE001 dose 1 (Type: EXPERIMENTAL): None
- OBE001 dose 2 (Type: EXPERIMENTAL): None
- OBE001 dose 3 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).